Home

Susan Moran

CIK 1835225 · CHIEF MEDICAL OFFICER · last filed 2026-06-03

Susan Moran is a CHIEF MEDICAL OFFICER who has filed 13 SEC Form 4 insider transactions across 4 companies since 2021. The most recent filing, for GLYC, was dated Jun 3, 2026. Current disclosed insider exposure totals $1.8K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.8K

Companies

4

Total Filings

13

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
1232 RICHARDSON AVE
LOS ALTOS, CA 94024
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director — $15.70 — $0 2 2026-06-03
TYRA Director — $28.65 — $0 3 2026-06-01
BCAB Director 1,046 $1.74 $1.8K $0 5 2025-06-18
RayzeBio, Inc. (RYZB) Delisted CHIEF MEDICAL OFFICER 0 $62.49 $0 $0 3 2024-02-27

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-03 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2026-06-01 TYRA Grant (A) — $0 EDGAR
2025-06-23 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2025-06-18 BCAB Grant (A) +23,500 $0 EDGAR
2025-06-02 TYRA Grant (A) — $0 EDGAR
2024-06-14 BCAB Grant (A) +16,500 $0 EDGAR
2024-05-09 TYRA Grant (A) — $0 EDGAR
2024-02-27 RayzeBio, Inc. (RYZB) Delisted Disp (D) −323,455 -$20.22M EDGAR
2024-02-06 RayzeBio, Inc. (RYZB) Delisted Exer (M) +30,875 $100.0K EDGAR
2023-11-17 RayzeBio, Inc. (RYZB) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.